ISSN:
1432-0851
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Patients with different types of cancer received treatment PO or IV with the new immunostimulating compound, 2-[2-cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, BM 12.531 (Prop. INN azimexon). After IV administration of 200 mg on 5 consecutive days or oral administration of 300 mg on 7 consecutive days a significant increase in the percentage of active T lymphocytes was seen. After in vitro incubation of different concentrations of BM 12.531 with blood from healthy donors there was a significant increase in the percentage of active T lymphocytes. No clear influence of BM 12.531 on the lymphocyte transformation caused by various concentrations of PHA could demonstrated because of the scatter. No side effects attributable to treatment with BM 12.531 were found, so that BM 12.531 is a good candidate for clinical trials.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00200211